Download - PERSONALISED MEDICINES AND THE REGULATORS Dr Mike James CambReg Consulting [email protected]
12 October 2012 2
Talk Outline
The ideal situationLegal requirementsSpecial considerations for new science
o MHRA Expert Advisory Group o CHMP Guidelineo Scientific Advice
Personalised medicines on the marketCompanion diagnostic methods
12 October 2012 4
Clinical Studies
The usual rules apply to personalised medicine studies:
clinical trial: any investigation in human subjects intended to discover or verify the clinical, pharmacological and/or other pharmacodynamic effects of one or more investigational medicinal product(s), and/or to identify any adverse reactions to one or more investigational medicinal product(s) and/or to study absorption, distribution, metabolism and excretion of one or more investigational medicinal product(s) with the object of ascertaining its (their) safety and/or efficacy (2001/20/EC)
12 October 2012 5
Key Requirements
GCP standard studies EC approval MHRA (or similar) acceptance of study:
o Quality data• Drug substance and drug product manufacture (GMP)• Specifications
o Safety data (if species restricted?)• Pharmacology• Toxicology
o Risk and Benefit statement
12 October 2012 6
Additional Considerations
Mechanism of action – do you really understand it?o Immunomodulators and TG1412 o MHRA Expert Advisory Groupo CHMP Paper (Guideline on Strategies to Identify and Mitigate Risks for First-in
Human Clinical trials with Investigational Medicinal Products)
12 October 2012 7
EAG Remit
FTIM studies with new compounds acting (directly or indirectly) via the immune system with a novel target or a novel mechanism of action or having a secondary potential effect on the immune system via a mechanism of action which currently is not well characterised
FTIM studies with novel compounds acting via a possible or likely species specific mechanism
Any FTIM studies which are otherwise seen as requiring expert advice Clinical trials involving classes of compound where MHRA may wish to
seek external expert advice or CHM may wish to have oversight Expert advice on whether a product’s mechanism of action is novel and
comes within the scope of the EAG Expert advice on pre-meeting scientific advice documentation for within
scope compounds Clinical trials where there is a difficult risk benefit balance Clinical trials where a new class safety issue has been identified
12 October 2012 8
First in Man Considerations - 1Risk FactorsMode of action
o Pleiotropic effect targetso Cytokine cascadeo (Knock out) animal modelso Relevance of animal models
Human targeto Cell and disease specificityo Expression and biological functiono Intra-subjects differences (healthy and patients)
12 October 2012 9
First in Man Considerations - 2
Qualityo Strength and potency
• Biological activity and link to non-clinical dose• What is a safe dose for humans?• Bioassay to control activity
o Qualification of materials• Even early studies require knowledge of what is
present (pharmacologically active impurities)o Dose
• Accuracy of small doses for steep dose-response
12 October 2012 10
First in Man Considerations - 3
Non-clinicalAnimal models and applicability to man
o Species restricted effects – animal studies less useful?
o In vitro human cell studies can be usefulo PD to address mode of actiono PK and toxicokinetics?
Calculation of human starting dose (NOAEL and/or MABEL)
12 October 2012 11
First in Man Considerations - 4
Clinical Caution is the watchword
o Study population (volunteers or patients)o Dose and dose escalation scheme
• First dose of active in a single subject• Observation period before second subject
o Facilities and staff suitable for emergency rescueo Justification for more than one site
12 October 2012 12
Examples of Real Personalised Medicines
Herceptin (Roche)o Antibody against HER2 protein on metastatic breast cancero Not all breast cancers over express HER2o Diagnosis of suitable patients – companion diagnostic
methods Provenge (Dendreon) – US only at present
o Autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer.
o Diagnosis of PC by conventional means (no special test kit)
12 October 2012 13
Herceptin (‘Main Stream’)
MoAb produced in CHO cellsApproved in Europe on 28 August 2000Serum and animal protein free systemLyophilised powder for reconstitution Development followed classical route for a
new entity with large clinical studiesApproximately £ 20 000 per patient per year
12 October 2012 14
Provenge (Advanced Therapy)
Activated autologous cell infusion Complex and costly product ($93,000 per course) Regulatory concerns:
o APC harvesting and transporto Incubation with fusion proteino Manufacture of fusion proteino Transport of activated producto Specifications linked to activity (increased survival)o Stability of activated APCo Animal models and pharmacology
12 October 2012 15
Provenge Treatment
Patient's own WBCs, primarily antigen presenting cells (APCs), are extracted by leucapheresis.
WBCs incubated with a fusion protein (PA2024) consisting of PAP (prostatic acid phosphatase present on 95% of prostate cancer cells) and GM-CSF that helps the APCs to mature.
Activated blood product is re-infused into the patient to cause an immune response against cancer cells carrying the PAP antigen.
Complete treatment is three courses with two weeks between successive courses
12 October 2012 16
Companion Diagnostic Kits
May be used foro selection of patients suitable for the medicationo optimal and individualised dosing o exclusion of populations expected to suffer from
severe adverse side effects At least 9 kits available in USA for HER2+ but
none from Roche at presentParallel development during clinical studies for
joint marketing?
12 October 2012 17
Regulation of Diagnostics
In vitro diagnostic devices (IVDs) controlled by Directive 98/79/EC (In Vitro Diagnostic Directive)
To be marketed a CE mark of conformity must be attached (by the manufacturer at present)
12 October 2012 19
Essential Requirements
Based on a risk approach of the IVD giving erroneous results in:
Analytical and diagnostic sensitivityAnalytical and diagnostic specificityAccuracyRepeatabilityReproducibility